Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report) last posted its earnings results on Tuesday, August 12th. Taysha Gene Therapies had a negative return on equity of 78.44% and a negative net margin of 1,144.97%. As a group, equities analysts anticipate that Taysha Gene Therapies, Inc. will post -0.35 EPS for the current year. Taysha Gene Therapies Company Profile(Get Free Report)Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. Recommended StoriesReceive News & Ratings for Taysha Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taysha Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.